In its most recent earnings release on Nov. 10, CRISPR said that Vertex has been seeing progress in the number of patients (currently around 300) being referred to treatment centers. Vertex sees ...
Zacks Investment Research on MSN
CRISPR Therapeutics AG (CRSP) is attracting investor attention: Here is what you should know
CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...
On the one hand, these stocks tend to have explosive growth potential, much more so than most of their larger counterparts.
Detailed price information for Ark Genomic Revolution ETF (ARKG-A) from The Globe and Mail including charting and trades.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback